Telomerase inhibitors in cancer therapy: Current status and future directions

Current Opinion in Investigational Drugs

Volumn 4, Issue 6, 2003, Pages 675-685

  Incles, Christopher M ^a   Schultes, Christoph M ^a   Neidle, Stephen ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

Antisense; G quadruplex; Telomerase; Telomere

Indexed keywords

2,3,7 TRICHLORO 5 NITROQUINOXALINE; 3 (3,5 DICHLOROPHENOXY)NITROSTYRENE; 6 THIO 7 DEAZA 2' DEOXYGUANOSINE 5' TRIPHOSPHATE; ACRIDINE; ANTISENSE OLIGONUCLEOTIDE; BENZOINDOLOQUINOLINE DERIVATIVE; BIBR 1532; BRACO 19; BRACO 20; BSU 6048; CATALYTIC INHIBITOR; CISPLATIN; CURCUMIN; DAUNORUBICIN; DOXORUBICIN; EPIGALLOCATECHIN GALLATE; ETHIDIUM DERIVATIVE; INDOMETACIN; NUCLEOSIDE ANALOG; OXALIPLATIN; PERYLENE; POLYPHENOL DERIVATIVE; PORPHYRIN; PROSTAGLANDIN SYNTHASE INHIBITOR; PSI 99A; RIBOZYME; RNA DIRECTED DNA POLYMERASE INHIBITOR; TELOMERASE; TELOMERASE INHIBITOR; TELOMESTATIN; TRIAZINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIDOVUDINE; ZIDOVUDINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CELL IMMORTALIZATION; DNA SYNTHESIS; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; ENZYME INHIBITION; HUMAN; NONHUMAN; REVIEW; SOMATIC CELL; TELOMERE;

ANIMALS; ENZYME INHIBITORS; FORECASTING; HUMANS; NEOPLASMS; TECHNOLOGY, PHARMACEUTICAL; TELOMERASE; TELOMERE;

EID: 0043167803     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. n among vertebrates. Proc Natl Acad Sci USA (1989) 86(18):7049-7053.
2. Blackburn EH: Switching and signalling at the telomere. Cell (2001) 106(6):661-673.
3. Cong Y-S, Wright WE, Shay JW: Human telomerase and its regulation. Microbiol Mol Biol Rev (2002) 66(3):407-425.
4. Harley CB, Futcher AB, Greider CW: Telomeres shorten during ageing of human fibroblasts. Nature (1990) 345(6274):458-460.
5. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PLC, Coviello GM, Wright WE, Weinrich RL, Shay JW: Specific association of human telomerase activity with immortal cells and cancer. Science (1994) 266(5193):2011-2015. Reports the discovery that telomerase is expressed in the overwhelming majority of tumors.
6. Meyerson M, Counter CM, Eaton EN, Ellisen LW, Steiner P, Caddle SD, Ziaugra L, Beijersbergen RL, Davidoff MJ, Liu Q, Bacchetti S et al: hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell (1997) 90(4):785-795.
7. Nakamura TM, Morin GB, Chapman KB, Weinrich SL, Andrews WH, Lingner J, Harley CB, Cech TR: Telomerase catalytic subunit homologs from fission yeast and human. Science (1997) 277(5328):955-959.
8. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell (2000) 100(1):57-70. A key survey of the molecular origins of human cancer, highlighting the role of telomere maintenance and telomerase.
9. Tomoda R, Seto M, Tsumuki H, Iida K, Yamazaki T, Sonoda J, Matsumine A, Uchida A: Telomerase activity and human telomerase reverse transcriptase mRNA expression are correlated with clinical aggressiveness in soft tissue tumours. Cancer (2002) 95(5):1127-1133.
10. Dunham MA, Neumann AA, Fasching CL, Reddel RR: Telomere maintenance by recombination in human cells. Nat Genet (2000) 26(4):447-450.
11. Hahn WC, Stewart SA, Brooks MW, York SG, Eaton E, Kurachi A, Beijersbergen RL, Knoll JHM, Meyerson M, Weinberg RA: Inhibition of telomerase limits the growth of human cancer cells. Nat Med (1999) 5(10):1164-1170. Demonstration of proof-of-principle, that inhibition of telomerase by means of a dominant-negative mutant results in senescence and telomere shortening.
12. Herbert BS, Pitts AE, Baker SI, Hamilton SE, Wright WE, Shay JW, Corey DR: Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death. Proc Natl Acad Sci USA (1999) 96(25):14276-14281. Study of antisense binding to the hTR template, demonstrating that this results in telomere shortening in cancer cells.
13. Pascolo E, Wenz C, Lingner J, Hauel N, Priepke H, Kaufmann I, Garin-Chesa P, Rettig WJ, Damm K, Schnapp A: Mechanism of human telomerase inhibition by BIBR 1532, a synthetic, non-nucleosidic drug candidate. J Biol Chem (2002) 277(18):15566-15572.
14. Barma DK, Elayadi A, Falck JR, Corey DR: Inhibition of telomerase by BIBR 1532 and related analogues. Bioorg Med Chem Lett (2003) 13(7):1333-1336.
15. Shay JW, Wright WE: Telomerase: A target for cancer therapeutics. Cancer Cell (2002) 2(4):257-265.
16. Hemann MT, Strong MA, Hao LY, Greider CW: The shortest telomere, not average telomere length, is critical for cell viability and chromosome stability. Cell (2001) 107(1):67-77.
17. Melana SM, Holland JF, Pogo BG: Inhibition of cell growth and telomerase activity of breast cancer cells in vitro by 3′-azido-3′-deoxythymidine. Clin Cancer Res (1998) 4(3):693-696.
18. Strahl C, Blackburn E: The effect of nucleoside analogs on telomerase and telomeres in Tetrahymena. Nucleic Acids Res (1994) 22(6):893-900.
19. Murkami J, Nagai N, Shigemasa K, Ohama K: Inhibition of telomerase activity and cell proliferation by a reverse transcriptase inhibitor in gynaecological cancer cell lines. Eur J Cancer (1999) 35(6):1027-1034.
20. Fletcher TM, Cathers BE, Ravikumar KS, Mamiya BM, Kerwin SM: Inhibition of human telomerase by 7-deaza-2′-deoxyguanosine nucleoside triphosphate analogs: Potent inhibition by 6-thio-7-deaza-2′-deoxyguanosine 5′-triphosphate. Bioorg Chem (2001) 29(1):36-55.
21. Kim JH, Kim JH, Lee GE, Lee JE, Chung IK: Potent inhibition of human telomerase by nitrostyrene derivatives. Mol Pharmacol (2003) 63(5):1117-1124.
22. Kim JH, Kim JH, Lee GE, Kim SW, Chung IK: Quinoxaline derivative: A potent telomerase inhibitor leading to cellular senescence of human cancer cells. Biochem J (2003): doi:10.1042/BJ20030363.
23. Elayadi AN, Demieville A, Wancewicz EV, Monia BP, Corey DR: Inhibition of telomerase by 2′-O-(2-methoxyethyl) RNA oligomers: Effect of length, phosphorothioate substitution and time inside cells. Nucleic Acids Res (2001) 29(8):1683-1689.
24. Chen Z, Corey DR: Telomerase inhibitors: A new option for chemotherapy. Adv Cancer Res (2003) 87:31-58. A thoughtful review on telomerase inhibition, analyzing the clinical potential of antisense oligonucleotides.
25. Chen Z, Monia BP, Corey DR: Telomerase inhibition, telomere shortening and decreased cell proliferation by cell permeable 2′-O-methoxyethyl oligonucleotides. J Med Chem (2002) 45(25):5423-5425.
26. Yatabe N, Wang Z, Inoue M: 2-5A antisense therapy directed against human telomerase RNA inhibits telomerase activity and induces apoptosis without telomere impairment in cervical cancer cells. Cancer Gene Ther (2002) 9(7):624-630.
27. Kim MM, Rivera MA, Botchkina IL, Shalaby R, Thor AD, Blackburn EH: A low threshold level of expression of mutant-template telomerase RNA inhibits human tumor cell proliferation. Proc Natl Acad Sci USA (2001) 98(14):7982-7987.
28. Schindler A, Fiedler U, Meye A, Schmidt U, Fussel S, Pilarsky C, Herrmann J, Wirth MP: Human telomerase reverse transcriptase antisense treatment downregulates the viability of prostate cancer cells in vitro. Int J Oncol (2001) 19(1):25-30.
29. Teng L, Specht MC, Barden CB, Fahey TJ: Antisense hTERT inhibits thyroid cancer cell growth. J Clin Endocrinol Metab (2003) 88(3):1362-1366.
30. Harrison JG, Frier C, Laurant R, Dennis R, Raney KD, Balasubramanian S: Inhibition of human telomerase by PNA-cationic peptide conjugates. Bioorg Med Chem Lett (1999) 9(9):1273-1278.
31. Yokoyama Y, Takahashi Y, Shinohara A, Wan X, Takahashi S, Niwa K, Tamaya T: The 5′-end of hTERT mRNA is a good target for hammerhead ribozyme to suppress telomerase activity. Biochem Biophys Res Commun (2000) 273(1):316-321.
32. Yokoyama Y, Takahashi Y, Shinohara A, Lian Z, Wan X, Niwa K, Tamaya T: Attenuation of telomerase activity by a hammerhead ribozyme targeting the template region of telomerase RNA in endometrial carcinoma cells. Cancer Res (1998) 58(23):5406-5410.
33. Kondo Y, Kondo S, Tanaka Y, Haqqi T, Barna BP, Cowell JK: Inhibition of telomerase increases the susceptibility of human malignant glioblastoma cells to cisplatin-induced apoptosis. Oncogene (1998) 16(17):2243-2248.
34. Lee KH, Rudolph KL, Ju YJ, Greenberg RA, Cannizzaro L, Chin L, Weiler SR, DePinho RA: Telomere dysfunction alters the chemotherapeutic profile of transformed cells. Proc Natl Acad Sci USA (2001) 98(6):3381-3386.
35. Nakajima A, Tauchi T, Sashida G, Sumi M, Abe K, Yamamoto K, Ohyashiki JH, Ohyashiki K: Telomerase inhibition enhances apoptosis in human acute leukaemia cells: Possibility of antitelomerase therapy. Leukemia (2003) 17(3):560-567.
36. Folini M, De Marco C, Orlandi L, Daidone MG, Zaffaroni N: Attenuation of human telomerase activity does not increase sensitivity of human melanoma cells to anticancer agents. Eur J Cancer (2000) 36(16):2137-2145.
37. Ludwig A, Saretzki G, Holm PS, Tiemann F, Lorenz M, Emrich T, Harley CB, Von Zglinicki T: Ribozyme cleavage of telomerase mRNA sensitizes breast epithelial cells to inhibitors of topoisomerase. Cancer Res (2001) 61(7):3053-3061.
38. Yang CS, Landau JM, Huang MT, Newmark HL: Inhibition of carcinogenesis by dietary polyphenolic compounds. Annu Rev Nutr (2001) 21:381-406.
39. Naasani I, Oh-Hashi F, Oh-Hara T, Feng WY, Johnston J, Chan K, Tsuruo T: Blocking telomerase by dietary polyphenols is a major mechanism for limiting the growth of human cancer cells in vitro and in vivo. Cancer Res (2003) 63(4):824-830.
40. Ramachandran C, Fonseca HB, Jhabvala P, Escalon EA, Melnick SJ: Curcumin inhibits telomerase activity through telomerase reverse transcriptase in MCF-7 breast cancer cell line. Cancer Lett (2002) 184(1):1-6.
41. Lonnroth C, Andersson M, Lundholm K: Indomethacin and telomerase activity in tumour growth retardation. Int J Oncol (2001) 18(5):929-937.
42. Simonsson T: G-quadruplex DNA structures - Variations on a theme. Biol Chem (2001) 382(40):621-628.
43. 3] G-tetraplex. J Mol Biol (1995) 251(1):76-94.
44. Parkinson GN, Lee MHP, Neidle S: Crystal structure of parallel quadruplexes from human telomeric DNA. Nature (2002) 417(6891):876-876-880. Crystal structure analyses of human quadruplexes demonstrates that under physiological conditions they unexpectedly assume an arrangement with all strands in a parallel orientation.
45. Schffitzel C, Berger I, Postberg J, Hanes J, Lipps HJ, Plückthun A: In vitro generated antibodies specific for telomeric guanine-quadruplex DNA react with Stylonychia lemnae macronuclei. Proc Natl Acad Sci USA (2001) 98(15):8572-8577.
46. Haider SM, Parkinson GN, Neidle S: Structure of a G-quadruplex-ligand complex. J Mol Biol (2003) 326(1):117-125.
47. Clark GR, Pytel PD, Squire CJ, Neidle S: Structure of the first parallel DNA quadruplex-drug complex. J Am Chem Soc 125(14):4066-4067.
48. Sun D, Thompson B, Cathers BE, Salazar M, Kerwin SM, Trent JO, Jenkins TC, Neidle S, Hurley LH: Inhibition of human telomerase by a G-quadruplex-interactive compound. J Med Chem (1997) 40(14):2113-2116. The first report that quadruplex-binding ligands can inhibit telomerase, demonstrating that disubstituted amidoanthraquinones have micromolar potency.
49. Harrison RJ, Gowan SM, Kelland LR, Neidle S: Human telomerase inhibition by substituted acridine derivatives. Bioorg Med Chem Lett (1999) 9(17):2463-2468.
50. Read MA, Harrison RJ, Romagnoli B, Tanious FA, Gowan SH, Reszka AP, Wilson WD, Kelland LR, Neidle S: Structure-based design of selective and potent G quadruplex-mediated telomerase inhibitors. Proc Natl Acad Sci USA (2001) 98(9):4844-4849. Rational structure approaches were used to design ligands with enhanced selectivity for the human 22mer G-quadruplex, and increased selectivity and potency for telomerase inhibition.
51. Alberti P, Ren J, Teulade-Fichou MP, Guittat L, Riou J-F, Chaires J, Hélène C, Vigneron J-P, Lehn J-M, Mergny J-L: Interaction of an acridine dimer with DNA quadruplex structures. J Biomol Struct Dyn (2001) 19(3):505-513.
52. Mergny J-L, Lacroix L, Teulade-Fichou M-P, Hounsou C, Guittat L, Hoarau M, Arimondo PB, Vigneron J-P, Lehn J-M, Riou J-F, Garestier T et al: Telomerase inhibitors based on quadruplex ligands selected by a fluorescence assay. Proc Natl Acad Sci USA (2001) 98(6):3062-3067. Describes the use of fluorescence-based assays to find new quadruplex-binding ligands.
53. Teulade-Fichou M-P, Carrasco C, Guittat L, Bailly C, Alberti P, Mergny J-L, David A, Lehn J-M, Wilson WD: Selective recognition of G-quadruplex telomeric DNA by a bis(quinacridine) macrocycle. J Am Chem Soc (2003) 125(16):4732-4740.
54. Alberti P, Schmitt P, Nguyen C-H, Rivalle C, Hoarau M, Grierson DS, Mergny J-L: Benzoindoloquinolines interact with DNA tetraplexes and inhibit telomerase. Bioorg Med Chem Lett (2002) 12(7):1071-1074.
55. Koeppel F, Riou J-F, Laoui A, Mailliet P, Arimondo PB, Labit D, Petitgenet O, Hélène C, Mergny J-L: Ethidium derivatives bind to G-quartets, inhibit telomerase and act as fluorescent probes for quadruplexes. Nucleic Acids Res (2001) 29(5):1087-1096.
56. Riou JF, Guittat L, Mailliet P, Laoui A, Renou E, Petitgenet O, Megnin-Chanet F, Hélène C, Mergny JL: Cell senescence and telomere shortening induced by a new series of specific G-quadruplex DNA ligands. Proc Natl Acad Sci USA (2002) 99(5):2672-2677. The first demonstration that G-quadruplex ligands affects telomere length and cell growth in cancer cells.
57. Gowan SM, Heald R, Stevens MFG, Kelland LR: Potent inhibition of telomerase by small-molecule pentacyclic acridines capable of interacting with G-quadruplexes. Mol Pharmacol (2001) 60(5):981-988.
58. Gowan SM, Harrison JR, Patterson L, Valenti M, Read MA, Neidle S, Kelland LR: A G-quadruplex-interactive potent small-molecule inhibitor of telomerase exhibiting in vitro and in vivo antitumor activity. Mol Pharmacol (2002) 61(5):1154-1162. Demonstration of senescence and antitumor activity by a potent trisubstituted acridine G-quadruplex ligand.
59. Han H, Cliff CL, Hurley LH: Accelerated assembly of G-quadruplex structures by a small molecule. Biochemistry (1999) 38(22):6981-6986.
60. Rossetti L, Franceschin M, Bianco A, Ortaggi G, Savino M: Perylene diimides with different side chains are selective in inducing different G-quadruplex DNA structures and in inhibiting telomerase. Bioorg Med Chem Lett (2002) 12(18):2527-2533.
61. Kim M-Y, Duan W, Gleason-Guzman M, Hurley LH: Design, synthesis, and biological evaluation of a series of fluoroquinoanthroxazines with contrasting dual mechanisms of action against topoisomerase II and G-quadruplexes. J Med Chem (2003) 46(4):571-583.
62. Izbicka E, Wheelhouse RT, Raymond E, Davidson KK, Lawrence RA, Sun D, Windle BE, Hurley LH, Von Hoff DD: Effects of cationic porphyrins as G-quadruplex interactive agents in human tumor cells. Cancer Res (1999) 59(3):639-644.
63. Grand CL, Han H, Munoz RM, Weitman S, Von Hoff DD, Hurley LH, Bearss DJ: The cationic porphyrin TMPyP4 down-regulates c-myc and human telomerase reverse transcriptase expression and inhibits tumor growth in vivo. Mol Cancer Ther (2002) 1(8):565-573.
64. Siddiqui-Jain A, Grand CL, Bearss DJ, Hurley LH: Direct evidence for a G-quadruplex in a promoter region and its targeting with a small molecule to repress c-Myc transcription. Proc Natl Acad Sci USA (2002) 99(18):11593-11598. Proof that quadruplexes can be formed from promoter sequences, and that this can be enhanced by ligand binding as a specific means of downregulating transcription.
65. Shin-Ya K, Wierzba K, Matsuo K, Ohtani T, Yamada Y, Furihata K, Hayakawa Y, Seto H: Telomestatin, a novel telomerase inhibitor from Streptomyces anulatus. J Am Chem Soc (2001) 123(6):1262-1263. Discovery of a novel, highly potent new class of telomerase inhibitor.
66. Kim M-Y, Vankayalapati H, Shin-Ya K, Wierzba K, Hurley LH: Telomestatin, a potent telomerase inhibitor that interacts quite specifically with the human telomeric intramolecular G-quadruplex. J Am Chem Soc (2002) 124(10):2098-2099.
67. Cuesta J, Read MA, Neidle S: The design of G-quadruplex ligands as telomerase inhibitors. Mini Rev Med Chem (2003) 3(1):11-21.
68. Griffiths JD, Comeau L, Rosenfield S, Stansel RM, Bianchi A, Moss H, De Lange T: Mammalian telomeres end in a large duplex loop. Cell (1999) 97(4):503-514.
69. Stewart SA, Ben-Porath I, Carey VJ, O'Conner BE, Hahn WC, Weinberg RA. Erosion of the telomeric single-strand overhang at replicative senescence. Nat Genet (2003) 33(4):492-496.
70. Li GZ, Eller MS, Firoozabadi R, Gilchrest BA: Evidence that exposure of the telomere 3′ overhang sequence induces senescence. Proc Natl Acad Sci USA (2003) 100(2):527-531.